File this under, “Half a loaf.”
After a two-year battle, a pair of public health advocacy groups obtained sought-after clinical trial data from regulators for two hepatitis C treatments sold by Gilead Sciences (GILD). But they failed to gain access to the most coveted information that would allow researchers to independently verify test results which were originally generated by the company.
About the Author Reprints
